Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA clearance updates or disposable sales trends in Iradimed’s dense SEC documents can feel like navigating an MRI suite with the lights off. Technical jargon about non-magnetic infusion pumps, detailed risk disclosures, and hundreds of pages of footnotes make the company’s filings uniquely challenging.
Stock Titan solves that problem. Our AI-powered summaries break down every Iradimed annual report 10-K simplified, each Iradimed quarterly earnings report 10-Q filing, and even the shortest Iradimed 8-K material events explained. The platform scans new releases on EDGAR in real time, tags anything related to FDA approvals, segment revenue, or supply-chain risks, and delivers plain-English takeaways you can act on.
Need to monitor executive activity? Receive instant alerts for Iradimed Form 4 insider transactions real-time so you never miss pivotal Iradimed insider trading Form 4 transactions. Want context on compensation? Jump straight to the Iradimed proxy statement executive compensation section without scrolling through exhibits. From tracking R&D spend patterns to comparing infusion-pump sales across quarters, our comprehensive coverage of all filing types lets investors answer practical questions such as “understanding Iradimed SEC documents with AI” or “Iradimed earnings report filing analysis” in minutes, not hours.
iRadimed CFO John Glenn reported significant insider transactions on June 20, 2025. The transactions involved:
- Acquisition of 5,796 shares through the vesting of Restricted Stock Units (RSUs)
- Disposition of 1,412 shares at $58.24 per share through share withholding for tax purposes
- Net beneficial ownership change to 13,151 shares held directly
The RSUs were originally granted on June 20, 2022, under iRadimed's 2014 Equity Incentive Plan, vesting in four equal annual installments starting June 20, 2023. This transaction represents the third vesting installment. The Form 4 was filed within the required reporting timeframe, demonstrating compliance with SEC disclosure requirements.
iRadimed held its Annual Meeting of Stockholders on June 19, 2025, where shareholders voted on three key proposals. All proposals passed successfully.
The voting results included:
- Board Elections: Five directors were elected with varying levels of support: - Hilda Scharen-Guivel received highest support (10.8M votes) - Anthony Vuoto (10.8M votes) - Monty Allen (9.5M votes) - Roger Susi (8.9M votes) - James Hawkins (8.4M votes)
- Auditor Ratification: RSM US LLP was confirmed as independent auditor with overwhelming support (11.8M votes in favor)
- Executive Compensation: Advisory resolution on executive compensation approved with strong support (10.8M votes in favor, 287K against)
The meeting demonstrated strong shareholder participation with approximately 11.8M total votes cast, including 709,490 broker non-votes on certain matters.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
What does Iradimed Corp specialize in?
How does Iradimed ensure the safety of its devices during MRI procedures?
Which healthcare settings benefit from Iradimed's products?
What are the core technologies behind Iradimed's products?
How does the company distribute its products?
How are Iradimed's products different from conventional medical devices?
What role does innovation play in Iradimed's business model?
Why is MRI compatibility important in modern healthcare?
